Your session is about to expire
← Back to Search
Tremelimumab monotherapy for Bladder Cancer
Study Summary
This trial is testing tremelimumab, an immunotherapy drug, as a possible treatment for patients with advanced solid tumors.
- Bladder Cancer
- Breast Cancer
- Pancreatic Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How does the efficacy of MEDI4736 + tremelimumab combination therapy compare to other treatments?
"The safety of MEDI4736 + tremelimumab combination therapy was rated as a 2. This is due to the fact that this is only a Phase 2 trial, so while there is some evidence supporting its safety, none exists for efficacy."
Are there other examples of MEDI4736 + tremelimumab being used together to treat patients?
"There are a total of 345 ongoing clinical trials for MEDI4736 + tremelimumab combination therapy. Out of those, 51 have progressed to Phase 3 testing. Although the majority of research is based in Cordoba, Texas, there are 13051 locations running trials worldwide."
Does this type of experiment with drugs happen often?
"The research and development of MEDI4736 + tremelimumab began in 2007. A clinical trial was conducted that same year and was sponsored by AstraZeneca. After the initial Phase 2 drug approval in 2007, which only involved 37 patients, there are now 345 live studies being conducted for this combination therapy across 1325 cities and 58 countries."
Are adolescents eligible to participate in this research project?
"The age bracket for patients that this trial is looking to enroll starts at 18 years old and ends at 150 years old."
Are there any volunteers still needed for this clinical trial?
"No, this particular trial is not recruiting patients at the moment according to its listing on clinicaltrials.gov. This information was last updated on November 8th, 2022. Although this study isn't looking for participants right now, there are 1848 other trials with open recruitment across a variety of medical fields."
Could I potentially take part in this research?
"In order to qualify for this study, potential patients must have a diagnosis of urinary bladder cancer and meet the age criteria of being between 18-150 years old. Currently, the trial is looking to enroll a total of 64 individuals."
What types of cancers does the MEDI4736 + tremelimumab combination therapy target?
"This combination therapy of MEDI4736 and tremelimumab is most often used to treat stage iii non-small cell lung cancer that cannot be removed through surgery. It can also be an effective treatment for metastatic ureter urothelial carcinoma and advance directives."
How many people have been approached to participate in this research?
"Presently, this study is not recruiting patients. The trial was first posted on November 2nd, 2015 and was last updated on November 8th, 2022. However, there are 1503 clinical trials for urinary bladder cancer and 345 studies for the MEDI4736 + tremelimumab combination therapy that are actively searching for participants."
Share this study with friends
Copy Link
Messenger